

# TERPENES



**Editor:**  
**Simone Carradori**

**Bentham Books**

# **Medicinal Chemistry Lessons From Nature**

*(Volume 2)*

*Terpenes*

Edited By

**Simone Carradori**

*Department of Pharmacy, G. d Annunzio  
University of Chieti-Pescara  
Italy*

## **O gf lekpndEj go kmt { 'Nguuqpu'Ht qo 'P cwtg**

*(Volume 4)*

*Vgtr gpgu*

Gf kqt: Uo qpg'Ecttcf qtk

ISSN (Online): 4; 94/562z

ISSN (Print): 4; 94/55; 8

ISBN (Online): ; 9: /; : 3/7345/86/9

ISBN (Print): ; 9: /; : 3/7345/87/6

ISBN (Paperback): ; 9: /; : 3/7345/88/3

©2023, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2023.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>FOREWORD</b> .....	i
<b>PREFACE</b> .....	iii
<b>LIST OF CONTRIBUTORS</b> .....	iv
<b>CHAPTER 1 SESQUITERPENES: A TERPENE SUBCLASS WITH MULTIFACETED BIOACTIVITIES</b> .....	1
<i>Antonella Di Sotto, Federico De Paolis, Marco Gulli, Annabella Vitalone and Silvia Di Giacomo</i>	
<b>INTRODUCTION</b> .....	1
<b>SESQUITERPENES</b> .....	9
<b>CARYOPHYLLANE SESQUITERPENES</b> .....	10
Chemistry and Distribution in Nature .....	10
Pharmacological Properties .....	14
<b>SESQUITERPENE LACTONES</b> .....	17
Chemistry and Distribution in Nature .....	17
Pharmacological Properties .....	21
<b>EREMOPHYLLANE SESQUITERPENES</b> .....	23
Chemistry and Distribution in Nature .....	23
Pharmacological Properties .....	27
Safety and Toxicological Concerns of Sesquiterpenes .....	31
<b>CONCLUDING REMARKS</b> .....	31
<b>CONSENT FOR PUBLICATION</b> .....	32
<b>CONFLICT OF INTEREST</b> .....	32
<b>ACKNOWLEDGEMENT</b> .....	32
<b>REFERENCES</b> .....	32
<b>CHAPTER 2 FROM <math>\Delta^9</math>-THC TO SYNTHETIC CANNABINOIDS: MULTI-FACETED THERAPEUTIC AGENTS AND VERSATILE SCAFFOLDS FOR DRUG DISCOVERY</b> .....	56
<i>Niccolò Chiaramonte and Nathalie Saraiva Rosa</i>	
<b>INTRODUCTION</b> .....	56
<b>HISTORY OF CANNABIS SATIVA L.</b> .....	56
Biogenesis of Phytocannabinoids .....	57
Total Synthesis of $\Delta^9$ -THC .....	59
Cannabinoid Receptors .....	62
Endocannabinoid System .....	64
Synthetic Cannabinoids .....	67
<b>INFERRING THE STRUCTURE-ACTIVITY RELATIONSHIP: CLASSICAL CANNABINOIDS DERIVED FROM <math>\Delta^9</math>-THC AND <math>\Delta^8</math>-THC</b> .....	67
Tricycle Scaffold .....	68
Geminal Dimethyl Function .....	70
Methyl Group in 9 .....	70
C-1 Hydroxyl Group .....	72
C-3 alkyl chain .....	76
<b>CONCLUSION</b> .....	82
<b>LIST OF ABBREVIATIONS</b> .....	82
<b>CONSENT FOR PUBLICATION</b> .....	83
<b>CONFLICT OF INTEREST</b> .....	83
<b>ACKNOWLEDGEMENTS</b> .....	83
<b>REFERENCES</b> .....	84

<b>CHAPTER 3 ENCAPSULATION OF ESSENTIAL OILS WITHIN LIPID-BASED FORMULATIONS FOR ENHANCED ANTIMICROBIAL ACTIVITY</b> .....	94
<i>Patrizia Paolicelli, Stefania Petralito, Jordan Trilli, Laura Di Muzio, Stefania Garzoli and Maria Antonietta Casadei</i>	
<b>INTRODUCTION</b> .....	94
<b>TERPENE HYDROCARBONS</b> .....	95
Oxygenated Compounds .....	96
<b>NANOENCAPSULATION OF ESSENTIAL OILS</b> .....	96
Liposomes .....	111
<b>SOLID LIPID NANOPARTICLES AND NANOSTRUCTURED LIPID CARRIERS</b> .....	121
Nanoemulsions and Microemulsions .....	125
<b>CONCLUDING REMARKS</b> .....	140
<b>CONSENT OF PUBLICATION</b> .....	141
<b>CONFLICT OF INTEREST</b> .....	141
<b>ACKNOWLEDGMENTS</b> .....	141
<b>REFERENCES</b> .....	141
<b>CHAPTER 4 ANTIMALARIAL ENDOPEROXIDES: FROM NATURAL SESQUITERPENE DRUGS TO A RISING GENERATION OF SYNTHETIC CONGENERS</b> .....	158
<i>Grazia Luisi</i>	
<b>INTRODUCTION</b> .....	159
<b>THE NATURE-DERIVED MAINSTAYS OF ANTIMALARIAL THERAPY</b> .....	160
<b>SESQUITERPENE LACTONE ENDOPEROXIDES: A NATURAL SOURCE OF 1,2,4-TRIOXANE-CONTAINING ANTIMALARIAL DRUGS</b> .....	164
The Class of Sesquiterpene Lactones .....	164
Sesquiterpene Lactone Endoperoxides: the Artemisinin Family .....	165
<i>The Discovery of the Nobel Molecule</i> .....	165
The Bioactivity Profile of Artemisinin .....	166
The Production of Artemisinin .....	167
Uncovering Artemisinin Structure and Key Determinants for Activity .....	167
<i>The Mechanism of Plasmocidal Action</i> .....	171
Resistance to Artemisinin .....	172
Artemisinin Derivatives and Analogs .....	173
Artemisinin Combination Therapy .....	183
Artemisinin Molecular Hybrids .....	184
Artemisinin Dimers and Trimers .....	199
<b>1,2-DIOXANE-, 1,2-DIOXOLANE-, 1,2,4-TRIOXANE-, 1,2,4-TRIOXOLANE-, AND 1,2,4,5-TETRAOXANE-BASED SYNTHETIC ENDOPEROXIDES AS ANTIMALARIAL CANDIDATES</b> .....	203
Dioxanes and Dioxolanes .....	204
<b>TRIOXANES AND TRIOXOLANES</b> .....	205
Trioxanes .....	205
<i>Trioxolanes</i> .....	207
<i>Tetraoxanes</i> .....	209
<b>CONCLUSION</b> .....	212
<b>CONSENT FOR PUBLICATION</b> .....	212
<b>CONFLICT OF INTEREST</b> .....	212
<b>ACKNOWLEDGEMENTS</b> .....	212
<b>REFERENCES</b> .....	213
<b>SUBJECT INDEX</b> .....	228

## FOREWORD

From the dawn of time, men resorted to Nature for all they need. No exception was made for health and, especially, pain. WHO estimated that almost 80% of people count on medicinal plants to take care of their “well-being” and here is the justification for the growing interest in the study of natural products and the development of their derivatives.

Among the wide range of molecules in the rich repository that Nature offers, we need to mention the terpene class, to which a whole volume of this book has been dedicated.

This volume aims to provide the readers with a brief and focused collection of some of the latest advances in the field with particular insight into the development of synthetic derivatives from a parent natural compound with highly promising bioactivity and the design of innovative formulations for possible administration.

Indeed, by scrolling through the volume index, the readers can find exciting novelty on terpenes-related topics in four well-organized chapters, including (1) a detailed overview of the sesquiterpenes polypharmacology; (2) an interesting journey around the cannabinoids world towards the development of new synthetic  $\Delta^9$ -THC derivatives; (3) the design of specific formulations to overcome the volatility issue of small sized terpenes-based essential oils; and (4) an update on the newest generations of endoperoxides endowed with antimalarial activity. Also, the interested audience is strongly encouraged to get more deepen understanding of the presented topics by a large number of selected references present in each chapter.

Notably, every topic dealt with in this volume, and in general in the whole book, fully describes the selected terpene scaffold in all the investigated MedChem and pharmaceutical points of view. Thus, detailed information on the design and synthesis of the compounds, their bioactivity and pharmacokinetics data, along with computational and formulation studies are provided.

The authors, also, discuss how the chemical modification of parent compounds affects biological or enzymatic activity and ADME profile, suggesting how to justify the changes in the activity/ADME data in MedChem terms.

Through the several examples of MedChem strategies to fix the most common issues on terpene derivatives, *e.g.* low potency and poor solubility, the authors drive the young researcher audience to derive general rules that could be useful in different experiments and studies they will perform. For these reasons, I strongly believe the book is addressed to a heterogeneous audience, comprising both expert and beginner MedChem scientists and pharmaceutical technologists and anyone who wants to update their knowledge on this broader and broader field of terpene research under the kind and helpful guidance of the authors, which are widely recognized scientists in Academia.



*ii*

In the next chapters, the readers will find recurrent concepts that we could summarize with the following keywords: #terpenes; #sesquiterpenes; #medicinalchemistry; #pain; #malaria; #naturalproducts; #optimization; #drugdesign; #bioactivity; #synthesis; #computationalchemistry; #biology; #chemistry; #formulation; and so on.

Good reading and taking notes.

**Dr. Ilaria D'Agostino Ph.D.**  
Department of Pharmacy  
G. d Annunzio University of Chieti-Pescara  
*Via dei Vestini 31, 66100 Chieti (Italy)*

## PREFACE

Natural products are often used in drug development due to their ability to provide unique and chemically diverse structures unmatched by any synthetic chemical collection. Medicinal Chemists have always been inspired by nature because natural products are often perceived as safer and for their capability to interact with biological targets. Indeed, in recent years, there has been emerging research on traditional herbal medicines based on their efficacy in the treatment of diseases for which they have been traditionally applied.

Conversely, natural compounds suffer from several issues such as scarce availability and seasonality, high differences in the production/extraction/isolation, low purity in commercial products from worldwide suppliers, and side effects. Moreover, due to their chemical complexity and the optional presence of different chiral centers, the total synthesis of a natural compound can be also challenging and expensive.

This book series would propose the latest discoveries in the field of compounds inspired by nature and obtained by chemical/enzymatic modification of a natural compound in the search for biologically active molecules for the treatment of human/animal ailments and permit the disposal of a wider arsenal for clinicians. The natural compounds are grouped into three clusters. The chapters are built in the following format: • General background on the (phyto)chemistry of the scaffold; • General background on the pharmacological profile of the scaffold; • Description of the proposed derivatives and their potentialities with respect to the parent compounds (with a particular emphasis on the synthetic approaches and structure-activity relationships); • *In silico* analysis of the crucial interactions with the biological target, when available; • Clinical studies and patent surveys (if available) on the new and proposed structures.

The readership of this book is represented primarily by Academies, Researchers, Specialists in the pharmaceutical field, Industry sector, Contract Research Organizations and hospitals dealing with clinical research.

**Simone Carradori**  
Department of Pharmacy  
G. d Annunzio University of Chieti-Pescara  
Italy

## List of Contributors

<b>Annabella Vitalone</b>	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
<b>Antonella Di Sotto</b>	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
<b>Federico De Paolis</b>	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
<b>Grazia Luisi</b>	Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy
<b>Jordan Trilli</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy
<b>Laura Di Muzio</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
<b>Marco Gulli</b>	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
<b>Maria Antonietta Casadei</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
<b>Nathalie Saraiva Rosa</b>	Royal College of Surgeons in Ireland, Department of Chemistry, Dublin, Ireland
<b>Niccolò Chiaramonte</b>	Royal College of Surgeons in Ireland, Department of Chemistry, Dublin, Ireland
<b>Patrizia Paolicelli</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
<b>Silvia Di Giacomo</b>	Department of Physiology and Pharmacology “V. Ersparmer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
<b>Stefania Petralito</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy
<b>Stefania Garzoli</b>	Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy

## CHAPTER 1

# Sesquiterpenes: A Terpene Subclass with Multifaceted Bioactivities

Antonella Di Sotto<sup>1,\*</sup>, Federico De Paolis<sup>1</sup>, Marco Gulli<sup>1</sup>, Annabella Vitalone<sup>1</sup> and Silvia Di Giacomo<sup>1</sup>

<sup>1</sup> Department of Physiology and Pharmacology V. Erspamer, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy

**Abstract:** Sesquiterpenes are terpene compounds, containing three isoprene units rearranged in a wide variety of structures. They occur widely in nature, not only in plants but also in fungi and marine environments. Owing to peculiar structures and diverse biological activities, they attracted great attention in pharmaceutical, medicinal chemistry and nutraceutical fields. The present chapter collects novel insights into chemistry, distribution in nature and pharmacological properties of sesquiterpenes, focusing especially on caryophyllane, lactone-type, and eremophilane subgroups, due to the growing pharmacological interest. Novel structures and alternative natural sources to be further investigated and exploited have been highlighted too. Moreover, some issues regarding toxicity risk and bioavailability of sesquiterpenes, which can limit their application in practice, have been discussed.

**Keywords:** Artemisinin, Alantolactone, Arglabin, Anticancer, Antimalarial, Antiinflammatory, Antimigraine,  $\beta$ -Caryophyllene, Capsidiol, Chemopreventive, Eremophilane,  $\alpha$ -Humulene, Helenalin, Isopetasin, Parthenolide, Petasin, Terpenes.

## INTRODUCTION

Terpenes are a large class of structurally diverse and widely distributed secondary metabolites, derived from a common basic building block, namely five-carbon isoprene unit (C<sub>5</sub>H<sub>8</sub>), assembled in linear chains or cyclic structures Table 1. More complex and functionalized terpenes, namely terpenoids, can also occur in nature [1].

---

\* Corresponding author Antonella Di Sotto: Department of Physiology and Pharmacology V. Erspamer, Sapienza University, Rome, Italy; E-mail: antonella.disotto@uniroma1.it

Table 1. Classification of terpene subclasses

Terpene Subclass	Isoprene Units	Number of Carbons
Monoterpenes	2	C10
Sesquiterpenes	3	C15
Diterpenes	4	C20
Sestertepenes	5	C25
Triterpenes	6	C30
Tetraterpenes	8	C40

Two major biosynthetic routes, namely the mevalonate (MVA) pathway and 2C-methyl-D-erythritol-4-phosphate (MEP) pathway (or Rohmer pathway), have been reported to be the terpene sources [2, 3]. The MVA pathway leads to the formation of the terpenoid C5 precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP): three molecules of acetyl-CoA are condensed to a 3-hydroxy-3-methylglutaryl-CoA, which is subsequently reduced to MVA, whose phosphorylation and further rearrangements lead to IPP and DMAPP (Fig. 1) In the MEP (or Rohmer) pathway, 1-deoxy-D-xylulose 5-phosphate, obtained by condensation of pyruvate and glyceraldehyde 3-phosphate, is converted into MEP which further leads to IPP and DMAPP, the basic building blocks of all terpene (Fig. 1).




Fig. (1). Biosynthetic pathways of terpenes: MVA or mevalonate pathway and MEP (2C-methyl-D-erythritol-4-phosphate) or Rohmer pathway.

Isoprene directly originates from IPP or DMAPP, while monoterpenes are synthesized from a geranyl pyrophosphate (GPP) precursor (also known as geranyl diphosphate or GDP), produced by the condensation of IPP and DMAPP (Fig. 2) [4]. GPP and one molecule of IPP can be condensed to farnesyl diphosphate (FPP), which can be further converted into different sesquiterpenes and triterpenes; furthermore, the addition of IPP to FPP leads to geranyl geranyldiphosphate (GGPP), from which diterpenes and tetraterpenes (or carotenoids) arise [4].

Terpenes are produced by a wide variety of plants, fungi and some animals, mediating antagonistic and beneficial interactions among organisms [2]. Particularly, high terpene levels have been found in plant reproductive structures and foliage, where they can act as allelopathic compounds, mediating plant biotic and abiotic interactions [1]. Indeed, some of them, especially volatile compounds, have been exploited by plants as a weapon against herbivores and pathogens; moreover, other compounds can mediate plant metabolic adaptation to climate changes and regulate cell membrane permeability due to their lipophilic nature [5]. For instance, in response to root feeding by caterpillars, corn (*Zea mais* L.) roots release the sesquiterpene  $\beta$ -caryophyllene, which is attractive to entomopathogenic nematodes and stimulates their killing ability against herbivore larvae [6].

The monoterpene ketone pulegone has been reported to be the main environmental defense released by *Mentha pulegium* L., while helivypolides, annulolides and helibisabonols are the most significant allelochemicals produced by sunflower (*Helianthus annuus* L.) [7, 8]. Similarly, monoterpenes and sesquiterpenes contained in the essential oil from *Cinnamomum septentrionale* Hand.-Mazz. produced phytotoxic effects against several species, such as *Taraxacum officinale* L. and *Eucalyptus grandis* L [8].

Another example of allelopathic interaction is the “*Salvia phenomenon*”, characterized by the ability of some *Salvia* species (i.e. *Salvia leucophylla* and *S. apiana*) to form a typical vegetation patterning in the soil in its vicinity, due to the production of monoterpenoids (i.e. camphor, 1,8-cineol,  $\beta$ -pinene,  $\alpha$ -pinene and camphene) which hinder the growth of other plants [8]. The phytotoxic effects of *Salvia* spp. have been also ascribed to the presence of di- and triterpene compounds, which include clerodane and neo-clerodane diterpenoids [9]; moreover, a number of phytotoxic diterpenes have been found in both plant and microorganisms [10].

Terpenes have attracted great scientific attention due to their multiple biological properties, thus strengthening the industrial interest in their application as

## CHAPTER 2

# From $\Delta^9$ -THC to Synthetic Cannabinoids: Multi-Faceted Therapeutic Agents and Versatile Scaffolds for Drug Discovery

Niccolò Chiaramonte<sup>1,\*</sup> and Nathalie Saraiva Rosa<sup>2,\*</sup>

<sup>1</sup> University of Antwerp, Laboratory of Medicinal Chemistry, Antwerp, Belgium

<sup>2</sup> Royal College of Surgeons in Ireland, Department of Chemistry, Dublin, Ireland

**Abstract:** *Cannabis sativa* L. has been used for millennia by humans for medicinal, ritual and recreational uses. Commonly known under its dried form (flowers and leaves) as marijuana, this plant produces hundreds of phytomolecules, including phytocannabinoids, terpenes and flavonoids. Over the past decades, it is most abundant and most therapeutically relevant component, (-)-*trans*- $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) has generated considerable interest due to its various therapeutic properties. Most of them result from the interaction with two G-protein coupled receptors named cannabinoid receptors (CB1 and CB2). This chapter gives a broad overview of the main structural investigations performed on the natural scaffold of  $\Delta^9$ -THC in order to modulate the affinity for the cannabinoid receptors and, potentially, its therapeutic properties. The design of several synthetic cannabinoid derivatives will be presented, and their structure-activity relationships will be analysed.

**Keywords:** Cannabinoids, Cannabinoid Receptors, Structure-Activity Relationship, Synthesis,  $\Delta^9$ -THC,  $\Delta^8$ -THC, Therapeutic Application.

## INTRODUCTION

### HISTORY OF CANNABIS SATIVA L.

*Cannabis sativa* L. is considered a very unique plant due to its history, chemistry, pharmacology, toxicology, and deep social impact. *Cannabis sativa* L. belongs to the family of Cannabaceae which includes only two genera (*Cannabis* and *Humulus*). The various subspecies of *C. sativa* L. identified so far mostly reflect the chemotype or geographical variants of a single taxonomic entity rather than distinct species [1]. It is one of the best characterized plant varieties with an


\* Corresponding authors Niccolò Chiaramonte and Nathalie Saraiva Rosa: University of Antwerp, Laboratory of Medicinal Chemistry, Antwerp, Belgium and Royal College of Surgeons in Ireland, Department of Chemistry, Dublin, Ireland; E-mails: niccolo.chiaramonte@uantwerpen.be and nathaliesaraivarosa@rcsi.ie

inventory of at least 489 natural compounds identified so far [2], comprising many different chemical classes, such as mono- and sesquiterpenes, sugars, steroids, flavonoids, hydrocarbons, nitrogen compounds, and especially cannabinoids, which are terpenophenolic compounds. Marijuana, a drug derived from *Cannabis sativa* L., is an illicit substance made mainly of the dried flowers and leaves of the plant which is sold in the illegal market. Despite the prohibitions, marijuana is the most cultivated, trafficked, and consumed drug in the world. This versatile crop has been used for millennia by humans, not only for recreational or ritual purposes but also for medicinal uses. Whereas its medicinal and psychoactive properties were well known for thousands of years, the elucidation of the mechanisms of actions of cannabis was only established in the late 19<sup>th</sup> century. Indeed, in 1843 Sir William B. O'Shaughnessy, an Irish physician, was the first to report on the medical use of cannabis, noting that hemp: “possesses, in small doses, an extraordinary power of stimulating the digestive organs, exciting the cerebral system, of acting also on the generative apparatus” [3]. The report also noted the ability of hemp oil to alleviate pain and to reduce seizures in infants. Cannabinol **1** was the first compound isolated in 1896 [4] and was initially considered as the active constituent of cannabis. Its chemical structure was fully elucidated only in 1940 (Fig. (1) [5, 6] together with the isolation of several other non-cannabinoid natural products, including cannabidiol **2** (CBD) [7]. Finally, the active component of cannabis, (-)- $\Delta^9$ -tetrahydrocannabinol **3** ( $\Delta^9$ -THC), was discovered in 1964 by Gaoni and Mechoulam, who reported its structure elucidation and its partial synthesis [8].

### Biogenesis of Phytocannabinoids

More than 100 natural products were isolated from *Cannabis sativa* L. and characterized mostly in the 1960s and 1970s [2, 9 - 11]. These compounds have been divided according to their structure into different classes, including the two predominant  $\Delta^9$ -THC **3** and CBD **2**, Cannabinol **1** (CBN), but also  $\Delta^8$ -*trans*-tetrahydrocannabinol **4** ( $\Delta^8$ -THC), Cannabigerol **5** (CBG) and Cannabichromene **6** (CBC) among others (Fig. 1).





**Fig. (1).** Main phytocannabinoids isolated in *Cannabis sativa* L.

The biogenesis of phytocannabinoids is summarized in Scheme (1) [12, 13]. The natural precursor *n*-hexanoylCoA **7** is transformed into olivetolic acid **9** through the tri-fold addition of malonyl-acetate derived units **8**, followed by cyclization and aromatization. A specific prenyltransferase catalyzes the condensation of **9** and geranyl phosphate (GPP, **10**) [14 - 16] to afford cannabigerolic acid (CBGA, **11**) which gives, after decarboxylation, cannabigerol **5**. It is nowadays generally accepted that the decarboxylation step for CBGA **11** and all the other cannabinoids is non-enzymatic and occurs spontaneously during either the storage, the extraction or the purification of the compounds. The oxidative intramolecular cyclization of **11** leads to the formation of cannabichromenic acid (CBCA, **12**) and, by decarboxylation, cannabichromene **6**. Moreover, the oxidation of CBGA **11** is also leading to the formation of a link between C-1 and C-6 of the prenyl unit, affording cannabidiol **2**, the main constituent of the fiber-type (non-psychotropic) varieties of *C. sativa*. This stereospecific intramolecular cyclization occurs through the cationic intermediate **13** and is catalysed by *CBDA synthase* [17], which has been isolated and characterized [18]. Another enzyme, *THCA synthase*, promotes the attachment of the phenolic oxygen leading to the formation of the tricyclic system of tetrahydrocannabinolic acid (THCA) **14**. As mentioned above, its decarboxylated analog Δ<sup>9</sup>-THC **3** is considered as an artifact since its concentration in extracts increases during storage, while simultaneously, the concentration of THCA **14** decreases. Numerous analogues sharing this terpenoid structural framework have been identified: Δ<sup>8</sup>-THC **4** shows

## Encapsulation of Essential Oils within Lipid-Based Formulations for Enhanced Antimicrobial Activity

Patrizia Paolicelli<sup>1,\*</sup>, Stefania Petralito<sup>1</sup>, Jordan Trilli<sup>1</sup>, Laura Di Muzio<sup>1</sup>, Stefania Garzoli<sup>1</sup> and Maria Antonietta Casadei<sup>1</sup>

<sup>1</sup> Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy

**Abstract:** Aromatic plants have been used since ancient times for their medicinal properties, including potent antimicrobial activity. Strong evidence indicates that plant extracts, in general, and essential oils (EOs), in particular, can act as effective antimicrobial agents against a wide spectrum of pathogenic microorganisms. However, their poor water solubility and stability, as well as their high volatility, make the administration of EOs to achieve the desired therapeutic effects particularly challenging. Therefore, these features severely limit the application of EOs in the pharmaceutical field. In this context, nanotechnology-based strategies for developing nano-scaled carriers for the efficient delivery of EOs might offer potential solutions. In particular, considering the lipophilic nature of EOs, lipid-based nanocarriers represent the most suitable vehicles for the effective encapsulation and delivery of EOs. This chapter provides an overview of the different chemical compositions due to various endogenous and/or exogenous factors of a selection of oils and the most recent lipid-based encapsulation strategies to enhance their antimicrobial activity and promote their pharmaceutical application.

**Keywords:** Antimicrobial Activity, Chemical Composition, Essential Oils, Encapsulation, Liposomes, Microemulsions, Nanoemulsions, Nanostructured Lipid Carriers, Solid Lipid Nanoparticles.

### INTRODUCTION

Essential oils (EOs) are very complex natural mixtures that can contain around 60 components at quite different concentrations. These volatile compounds extracted from plants or plant organs like flowers, seeds, buds, leaves, fruits, wood, roots, barks and twigs are responsible for the characteristic flavour and aroma. There are several methods for extracting EOs: by use of liquid carbon dioxide or microwaves, by distillation (*via* steam and/or water) or mechanical methods, such

\* Corresponding author Patrizia Paolicelli: Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Rome, Italy; E-mail: patrizia.paolicelli@uniroma1.it

as cold pressing. The aromatic chemicals that give the typical essence to each oil are extracted and combined with carrier oil.

EOs can be applied in various cases, including pharmaceutical and health industries but are most commonly used in the practice of aromatherapy; they are also used in a wide range of consumer goods, such as soaps, detergents, toilet products and cosmetics. EOs are obtained from aromatic flora or plants bearing many Angiospermic families, such as Rutaceae, Lamiaceae, Myrtaceae, Asteraceae and Zingiberaceae [1]. All EOs have their own unique smell and potential health benefits, such as for treating insomnia (lavender oil), as an antibiotic and antimicrobial (peppermint and tea tree oils) or as an anti-inflammatory (cumin and rosemary oils). The presence of a variety of diverse constituents in EOs could be responsible for wide spectrum of biological activities of the plant.

EOs are products of an unregulated sector, and the quality and their chemical composition can vary greatly. In this regard, it is very important that an EO is pure and of high quality, that it is free of synthetic additives and that has not been modified during the extraction process from the plant.

The main volatile constituents of EOs are terpenes, organic compounds consisting of multiples of isoprene units (containing five carbon atoms) and linear-chain, aromatic or heterocyclic compounds. Different combinations of the isoprene units originate structurally and functionally different classes of terpenes [2]. When a terpene contains oxygen, it is called a terpenoid.

Generally, hydrocarbons and oxygenated compounds such as alcohols, aldehydes, ketones, acids, esters, and oxides are responsible for odors and the characteristic aroma. The analytical technique useful for determining the chemical composition of EOs is gas chromatography. There are many reports in the literature that have contained useful information about the composition of different EOs [3 - 5]. EOs are complex materials and multi-component systems classified into non-volatile, semi-volatile, and volatile compounds according to their nature. Furthermore, the chemical composition of EOs depends on the place of origin, climatic conditions, and plant species [6]. By the analysis of EO, the following compounds are found in varying proportions, and they are the main groups [7]:

### **TERPENE HYDROCARBONS**

-Monoterpene hydrocarbons: found in almost all EOs and have a structure of 10 carbon atoms and at least one double bond. The 10 carbon atoms are derived from two isoprene units.

-Sesquiterpenes: they consist of 15 carbon atoms and have complex pharmacological actions.

Monoterpenes, diterpenes, and sesquiterpenes are the main groups of terpenes found in spices and herbs; they have notable biological activities such as antimicrobial effects on different pathogens [8, 9].

### **Oxygenated Compounds**

- Phenols: some examples are thymol, eugenol and carvacrol. These components have great antiseptic, antibacterial and disinfectant qualities.
- Alcohols: they are divided into monoterpene and sesquiterpene alcohols, such as linalool, citronellol, terpineol and bisabolol.
- Aldehydes: they have antifungal, anti-inflammatory, disinfectant, and sedative therapeutic properties.
- Ketones: they can be toxic, but they also have some great therapeutic benefits.
- Esters: like linalyl acetate, they are normally very fragrant and tend to be fruity and their therapeutic effects include sedative and antispasmodic activities.
- Ethers: the most common are the phenolic ones, such as the anethole present in anise.
- Oxides: the main therapeutic effect of oxides is that of expectorant, with 1,8-cineole, commonly known as eucalyptol, the best known.

Finally, lactones and coumarins can also be found.

The chemical profile of an EO, even obtained from the same species, may differ according to the geographical source and the harvest season of a particular plant species and also for the same species from different regions [10 - 13]. Genotype, interaction with the environment and agronomic conditions, such as the age of the plant, the degree of maturity of the plant, the harvest time and the composition of the soil, can influence the quali-quantitative composition of EO [11, 14]. Furthermore, the extraction product can vary in quality and/or quantity depending on the type of extraction method chosen [15].

In this regard, Table 1 shows different chemical compositions of a selection of EOs endowed with antimicrobial properties. They have been selected on the base of the formulation studies reported in the following paragraphs.

### **NANOENCAPSULATION OF ESSENTIAL OILS**

EOs represent an important part of the traditional Pharmacopeia [115]. Nowadays, a large number of biological activities have been reported for EOs to prevent and treat human diseases, and, in particular, a lot of evidence exists on their antimicrobial properties [116, 117].

## Antimalarial Endoperoxides: from Natural Sesquiterpene Drugs to a Rising Generation of Synthetic Congeners

Grazia Luisi<sup>1,\*</sup>

<sup>1</sup> Department of Pharmacy, University G. d Annunzio of Chieti-Pescara, 66100 Chieti, Italy

**Abstract:** Malaria is a vector-borne tropical disease caused by protozoans belonging to the genus *Plasmodium*, which has been scourging mankind for hundreds of millions of years. Despite the masterful progress in preventing disease transmission and reducing morbidity and fatal outcomes, malaria is on the rise again. Global concerns are focused on the spread of resistance to current drugs in the management of severe or ultimately lethal *P. falciparum* infection. To fully exploit the potential of existing agents and overcome their critical drawbacks, novel synthetic and formulation approaches have been explored. In this field, the clinical value of the natural drug artemisinin (ART) and its derivatives have been firmly established, and ART combination therapies (ACTs) have been recommended as first-line treatment against infection caused by chloroquine-resistant (CQR) *P. falciparum* strains. Over time, however, ART treatment options have become inadequate, and strict demand for new and effective agents has emerged. In this chapter, the medicinal chemistry aspects of artemisinins will be discussed, covering their unique mode of action and their structural features in relation to stability, pharmacokinetic profile, and antiplasmodial activity. Beyond ACT strategies, significant classes of compounds obtained through both ART covalent bitherapy and dimerization approaches will be presented as well. Furthermore, a special section will focus on the most recent endoperoxide-based synthetic antimalarials as new powerful and cost-effective alternatives to the “golden drug”. It is expected that reported results will provide a strong incentive for further studies, and that unceasing research efforts will succeed in reaching the eventual eradication of this endemic plague.

**Keywords:** Antimalarial drugs, Artemisinin (ART), Artemisinin combination therapy (ACT), Chloroquine (CQ), Covalent bitherapy, Endoperoxides, Iron(II)protoporphyrin IX, Malaria, Molecular hybridization, Multidrug-resistant, Ozonides, Protozoan, *Plasmodium* spp., Sesquiterpene, 1,2,4,5-tetraoxanes, 1,2,4-trioxanes, 1,2,4-trioxolanes, World Health Organization (WHO).

\* Corresponding author **Grazia Luisi:** Department of Pharmacy, University G. d Annunzio of Chieti-Pescara, 66100 Chieti, Italy; E-mail: grazia.luisi@unich.it

## INTRODUCTION

Malaria is a devastating, vector-borne parasitosis caused by ancient unicellular protozoans of the genus *Plasmodium*, members of the large Apicomplexa taxon. This plague is endemic in tropical and sub-tropical regions, affecting approximately 40% of the world's population. Although malaria ranks fourth among the major human infectious diseases, after pneumococcal acute respiratory infections, acquired immunodeficiency syndrome (AIDS) and tuberculosis (TBC), it is recognized that *Plasmodium* spp. represent the deadliest parasite species throughout the history of mankind [1]. The reasons for parasite survival and continued infection in the human race are the results of an intricate evolutive interplay between hosts, pathogens, and infected vectors, deeply connected with climatic and socio-economic variables.

Over time, an impressive advance in antiplasmodial prophylaxis, chemotherapy, and transmission control through national malaria campaigns has been made, culminating in a sensible decline in disease incidence and associated mortality in many areas of the world in the last decade [2]. According to the World Health Organization (WHO), in 2019, malaria affected 229 million people, with 22 million fewer cases than in 2010 [3]. Unfortunately, in recent years the decrease in malaria burden has stagnated, owing to the persistence of critical conditions in endemic regions that undermine the success of therapeutic/prophylactic protocols and vector containment programs. However, the main causative factor for this *debacle* resides in the great genetic variability of the etiologic agent, leading to a highly adaptive response under widespread drug pressure.

The case of parasite drug resistance is ideally exemplified by the first-line antimalarial agent chloroquine (CQ); introduced in 1950s, this very effective and remarkably cheap drug was the most widely used in the 4-aminoquinolines class for the treatment of uncomplicated *Plasmodium falciparum* malaria till the emergence, over the course of 30 years, of chloroquine-resistant *P. falciparum* (CRPF) strains. The main mechanism of resistance envisions subsequent mutations in the gene *Pfcr*, which encodes for the parasite CQ resistance transporter (*PfCRT*) protein, whose amplification leads to an enhancement in the extrusion of the xenobiotic from the digestive vacuole (DV) of the protozoan [4, 5]. Moreover, the degree of resistance can be modulated by polymorphisms in the *P. falciparum* multidrug resistance-1 (*PfMDR1*) protein, an ABC transporter that also regulates the flux of CQ across the DV membrane [5, 6].

An important contributor to resistance is the elimination time of the dispensed agent from the body; by administering drugs with short half-lives, the window of selection (*i.e.*, the time during which antimalarial drugs persist at sub-therapeutic

concentrations) for drug tolerance and resistance are minimized. Accordingly, at least till 2008, there was no evidence for clinically relevant resistance of *Plasmodium* parasites to artemisinin, a superior drug for the treatment of multidrug-resistant *falciparum* malaria, possessing a very short half-life (~ 1-3 h). The approach of ART co-formulation with a second, longer-acting antimalarial, commonly termed artemisinin combination therapy (ACT), has emerged as a means to confer greater protection against the development of drug-resistant mutants, preserving the effectiveness of ART and the partner agent in the time.

Furthermore, present *Plasmodium* species are the result of a hundred million years of apicomplexan evolutionary adaptation to increasingly elaborate host innate and acquired immunity, and consequently display a high degree of antigen variability to escape such defenses, and to arrange alternative invasion pathways through the generation of functionally redundant ligands for human cell receptors [7, 8]. This scenario emphasizes the need to broaden the range of therapeutic targets and the variety of replacement agents in order to overcome the current protocols' drawbacks and delay antimalarial resistance for the longer-term goal of malaria elimination. Recent advances in our understanding of biology and genomics of malaria parasites may provide information for putative novel structures to be targeted, and help in designing new generations of anti-malarial drugs based on unexplored chemotypes and acting with different mechanisms. On these bases, plentiful strategies for anti-malarial drug discovery are currently inquired, and progress in high throughput screening and computer-aided technologies offers exciting opportunities for developing suited candidates.

A mention of the general aspects of the vector-borne disease could not be presented here for brevity's sake, and readers are then referred to the overwhelming literature existing on the topic [9 - 20]. However, a brief excursus on the antimalarial drugs currently in use will introduce the special focus on the ART "miracle molecule" and its congeners.

## **THE NATURE-DERIVED MAINSTAYS OF ANTIMALARIAL THERAPY**

The existing antimalarial therapeutic arsenal owes a great tribute to nature since most of the curative molecules derive from medicinal plants, fungi, and microorganisms. The therapeutic effect of herbal medicines traditionally used by local communities was confirmed and defined by time, and natural agents such as quinine, artemisinin, febrifugine, and lapachol have been the cornerstone of antimalarial treatment for thousands of years. Again, antimalarial screening of natural products from fungal and microbial sources, of both terrestrial and marine provenience, has revealed a wide potential in view of their chemical diversity [21, 22].

## SUBJECT INDEX

### A

- ABC transporter 159  
 Acetal 168, 175, 186  
     ester connection 186  
     functionalities 168, 175  
 Acetylation 199  
 Acid 5, 23, 58, 60, 61, 62, 65, 70, 122, 125,  
     138, 166, 167, 170, 173, 174, 176, 179,  
     186, 191, 192, 195, 209  
     abietic 5  
     artesianic 166, 170, 173, 176, 195  
     cannabichromenic 58  
     cannabigerolic 58  
     carboxylic 186  
     carnosic 5  
     catalyzed peroxidation 209  
     dihydroartemisinin 167  
     eremophilane 23  
     ferulic 122, 125  
     olivetolic 58  
     tetrahydrocannabinolic 58  
     thioctic 138  
 Acidophilus 117  
 Acquired immune deficiency syndrome 63  
 Activation 4, 15, 16, 22, 29, 30, 62, 63, 171,  
     172, 179  
     reduced 29  
     reductive 171  
     suicide 22  
 Activity 73, 74, 75, 77, 79, 117, 120, 123,  
     124, 126, 127, 132, 133, 134, 135, 138,  
     139, 140, 165, 166, 169, 170, 179, 199,  
     201  
     anti-amastigote 135  
     antibiofilm 120, 126, 127  
     antifungal 117  
     antileishmanial 135  
     antitumor 199  
     bacteriostatic 127  
     biocidal 140  
     fungicidal 138  
     gametocidal 201  
     insecticidal 165  
     leishmanicidal 134  
     metabolic 138  
     nanomolar 170  
     nonmalarial 166  
 Acyclic sesquiterpenes 10  
 Adducts 171, 199, 201  
     dimeric 201  
     non-polymerizable covalent 171  
 Adenosine triphosphate 64  
 Adenyl cyclase 64  
 Adhesive glucan 137  
 AEO-loaded liposomes 118  
*Aesculus hippocastanum* 6  
 Agents 5, 23, 29, 32, 125, 161, 166, 174, 183,  
     197  
     anti-inflammatory 23  
     anti-proliferative 125  
     chemotherapeutic 5, 23  
     hypolipidemic 32  
     traditional 161  
 Airway hyperresponsiveness 29  
 Allergic reactions 167  
*Allium sativum* 102  
 Amazonensis 135  
 Amorphane sesquiterpenes 167  
 Antibacterial 5, 8, 10, 14, 21, 22, 96, 112, 116,  
     117, 118, 119, 123, 124, 126, 128, 134,  
     135, 136, 137  
     activity 22, 116, 117, 118, 123, 124, 134,  
     135, 137  
     agent 128  
     antioxidant mouthwashes 117  
     properties 119, 136  
 Anti-biofilm agent 137  
 Antibiotic 138, 140  
     neomycin 138  
     resistance 140  
 Anticancer 1, 5, 7, 14, 23, 123, 165  
     activity 23  
     effects 5



## Subject Index

Antiemetic effect 63  
Antifungal activity 27, 116, 125, 126, 127, 132, 133, 137  
Antifungal agent 115, 118, 123  
Antigen-induced degranulation 30  
Anti-inflammatory 15, 29, 30  
  activity 15  
  effects 15, 29, 30  
  power 29  
Antimalarial 1, 21, 22, 158, 160, 165, 166, 169, 171, 172, 176, 180, 182, 194, 195, 203, 205, 207, 212  
  activity 22, 169, 171, 172, 176, 180, 194, 195, 203, 205, 207  
  conventional 166  
  endoperoxide-based synthetic 158, 212  
  therapy 160, 212  
  treatment 160  
Antimicrobial 4, 22, 96, 111, 114, 115, 122, 123, 124, 133, 137, 138, 139, 140, 141  
  agents 114, 115, 122, 137, 138, 139, 141  
  effects 22, 96  
  properties 4, 96, 111, 124, 133, 140  
  resistance 123  
Antimicrobial activity 94, 116, 118, 119, 120, 121, 123, 124, 127, 133, 135, 136, 137, 138, 139, 140, 141  
  of nanoemulsions 127  
  of solid lipid nanoparticles 121, 123  
Anti-migraine effects 30  
Antimycobacterial agent 128  
Antinociceptive effects 15  
Antioxidant 4, 8, 10, 14, 16, 21, 112, 117, 123  
  enzymes 16  
  properties 8  
Antiparasitic 8, 112  
  effects 112  
Antiplasmodial activity 158, 170, 171, 187, 197, 199, 212  
*Apium graveolens* 128  
Apoptosis 15, 22, 171  
Application 3, 4, 5, 19, 56, 61, 71, 82, 109, 110, 114, 115, 120, 121, 122, 123, 127, 128, 129, 133, 139  
  industrial 61

## Medicinal Chemistry Lessons From Nature, Vol. 2 229

  mucosal 133  
  therapeutic 19, 56, 71, 82  
Aromatherapy 95  
ART 158, 167, 180, 184, 187, 196  
  based hybrid compounds 184  
  combination therapies 158  
  covalent bitherapy 158  
  pharmacophore 187  
  plasmocidal mechanism 180  
  production 167  
  thymoquinone hybrids 196  
  treatment 158  
Artelinic acid 173, 179, 187, 191, 192  
  congener 179  
  chloroquine hybrids 191  
  primaquine conjugate 192  
*Artemisia annua* 20, 21, 101, 114, 115, 129  
Artemisinin 31, 173, 184  
  derivatives 31, 173  
  molecular hybrids 184  
Arylglycosylamines 178  
*Aspergillus ochraceus* 27  
Assay 29, 119, 138  
  carrageenan-induced rat hind paw oedema 29  
Assembling procedures 180  
Asthma 30  
  allergic 30  
Asymmetric catalysts 61  
Asymptomatic liver phase 162

## B

*Bacillus subtilis* 27  
Bacteria 5, 8, 10, 117, 137, 138, 164  
  cariogenic 117  
  colonic urea-splitting 138  
Bactericidal 119, 134  
  activity 134  
  effect 119  
*Bathydoris hodgsoni* 9  
Bilayers 111, 116, 119  
  phospholipidic 119

- Bioavailability 1, 4, 9, 16, 32, 117, 173, 184, 208, 212  
  ameliorate 173  
  oral 208  
Biofilm formation 119, 127, 137  
  inhibiting 137  
Biosynthetic pathways 2, 9, 200  
  of sesquiterpenes 9  
  of terpenes 2  
Bronchodilator effects 5
- C**
- Cadinanolides 17  
Cancer 8, 15, 22, 63, 184  
  breast 8  
  chemotherapy 63  
Candidiasis 125, 127, 130, 133  
  topical 125  
  vaginal 130, 133  
  vulvovaginal 127  
Cannabinoid(s) 56, 57, 58, 61, 62, 63, 67, 68, 70, 72, 77, 80, 81  
  activity 77  
  agent 77  
  consumption 63  
  derivatives 68, 70, 80, 81  
  endogenous 62  
  non-psychoactive 62  
Cannabis 56, 57, 62, 64, 67  
  meroterpenoids 67  
*Capsicum annuum* 27  
Cardiovascular 63  
  failures 63  
  functions 63  
Carotenoids 3, 4, 8  
Cellular dysfunction 171  
Central nervous system (CNS) 62, 63, 64  
Cerebral malaria 196, 197  
Cerebrovascular 196, 197  
  dysfunction, associated 196  
  flow 197  
Chamaecyparis nootkatensis 26  
Chemical 82, 164  
  heterogeneity 164  
  manipulations 82  
Chemotherapy 63, 159  
  induced nausea 63  
Chinese medicinal plant 165  
Chitosan films 134  
Chlorhexidine digluconate 138  
Chloroquine-resistant *P. falciparum* (CRPF) 159  
Cholesterol 114, 117, 118, 119  
  multilamellar vesicles 114  
  unilamellar vesicles 114  
*Chrysopogon zizanioides* 26  
Cigarette smoke 16  
*Cinnamomum* 3, 131  
  *septentrionale* 3  
  *zeylanicum* 131  
Cinnamon oil 120  
  hinders 120  
*Citrus sinensis* 104, 130  
*Cladosporium cladosporioides* 27  
Cleavage 22, 203  
  catalyzed hemolytic 203  
Clindamycin 163  
CLP-loaded liposomes 116  
Collagen deposition 124  
Combination therapies 179, 212  
Commercial antifungal cream 127  
Computer-aided technologies 160  
Concentrations 16, 31, 58, 94, 118, 120, 127, 160  
  cytoplasmic calcium 31  
  nontoxic 16  
  phospholipid 118  
Conditions 96, 199  
  agronomic 96  
  metabolic 199  
  radiation 199  
Confocal laser scanning microscopy (CLSM) 135, 137  
Contraction, wound 124  
*Corynebacterium diphtheriae* 22  
Couple, endoperoxide oxygen 186  
*Cuminum cyminum* 108, 128  
Cutaneous leishmaniasis 134

## Subject Index

Cyclic 64, 120  
  adenosine monophosphate 64  
  oligosaccharides 120  
Cyclizations 10, 58  
  oxidative intramolecular 58  
  stereospecific intramolecular 58  
Cyclooxygenase 15  
*Cymbopogon* 103, 114, 115, 128, 129, 130, 135  
  *citratus* 128, 135  
  *densiflorus* 114, 115  
  *flexuosus* 103, 128, 129, 130  
*Cynara scolymus* 20  
Cynaropicrin 20, 23  
Cysteine 19, 165, 197  
  proteases 197  
  residues 19, 165  
Cytoprotective 15, 16  
Cytosporinols 12, 13, 14  
Cytotoxic 8, 10, 14, 134, 182  
  produced 8  
  sesquiterpenes 14

## D

Defenses 31, 160  
  impaired antioxidant 31  
Delivery systems 4, 19, 138  
  self-nanoemulsifying drug 138  
Delivery vehicle 111, 114, 115, 121, 122, 123, 127, 128, 129, 130, 131, 132, 140, 141  
  lipid-based 140  
Dental intracanal disinfection 138  
Depressant effects 29  
Derivatives 12, 13, 31, 74, 75, 77, 79, 80, 158, 162, 166, 169, 171, 173, 174, 179, 181  
  caryophyllene 12  
  cycloalkane 77  
  fluorinated 74  
  metabolic 31  
  polycyclic 13  
Diabetes 8, 16  
Diacylglycerol lipase 66  
Diffusion assay 118, 132, 136

## Medicinal Chemistry Lessons From Nature, Vol. 2 231

Digestive 57, 63, 159, 189, 191, 193, 194, 197  
  organs 57  
  tract motility 63  
  vacuole (DV) 159, 189, 191, 193, 194, 197  
Diseases 8, 9, 15, 27, 32, 116, 117, 123, 125, 160, 184  
  autoimmune 15  
  coronary heart 8  
  dysmetabolic 32  
  eye 8, 9  
  inflammatory 15  
  metabolic 27  
  neurodegenerative 9  
  oral cavity 116, 117  
  proliferative dermal 125  
DNA 15, 16, 23  
  binding 23  
  -damage 16  
  fragmentation 15  
Downstream effects 65  
Dravet syndrome 59  
Drug(s) 16, 30, 82, 111, 119, 132, 138, 139, 159, 160, 162, 169, 170, 171, 173, 174, 183, 184, 186, 194, 196, 199, 200, 211, 212  
  anti-allergic 30  
  anticancer 16  
  antifolate 200  
  antifungal 132  
  anti-malarial 160, 194  
  conventional antibacterial 119  
  hybrid 196  
  hydrophobic 111  
  synthetic cannabinoid 82  
  tolerance 160  
  water-soluble 170

## E

Efficacy 16, 30, 109, 112, 116, 124, 127, 132, 135, 136, 137, 183, 184  
  antifungal 127  
  synergic 183, 184  
Electron withdrawing effect 174

Electrospinning 134  
Electrostatic repulsion 140  
Elemanolides 17  
*Elettaria cardamomum* 97  
Emesis, chemotherapy-induced 63  
Emulsions, conventional 126, 137, 138  
Enantioselectivity 61  
Encapsulation process 140  
Encountered global application 172  
Endocannabinoid 64, 65  
    signaling 65  
    system 64, 65  
Endodontic treatment 138  
Endoperoxides 158, 161, 163, 164, 165, 173,  
    199, 203, 204, 205  
    phytochemical 204  
    plant-derived sesquiterpene lactone 163  
    sesquiterpene lactone 161, 164, 165  
Energy 113, 121, 182  
    bond dissociation 182  
    mechanical 113  
Entomopathogenic nematodes 3  
Enzymatic polycyclization 11  
Enzymes 10, 17, 22, 58, 65, 167, 174  
    cyclase 17  
    farnesyl protein transferase 22  
    key 22, 167  
    oxidase 17  
    oxidative 174  
Epigenetic machinery deregulation 31  
Eremophilanes 1, 23, 31  
Erythromycin 135, 136  
Erythropoiesis 167  
*Escherichia coli* 27, 128  
Esophageal tumors 23  
Esterification 197  
*Eucalyptus grandis* 3  
*Eugenia caryophyllata* 98, 122

## F

Fast-degradable nanofibers 134  
Fatty acid amide hydrolase (FAAH) 15, 65  
Ferulic acid, antioxidant 125

Fibroblast infiltration 124  
Function 16, 29, 62, 65, 119, 136  
    cardiac contractile 29  
    immune cell 62  
Fungal metabolites 8  
Fungi 1, 3, 5, 8, 10, 11, 12, 14, 19, 27, 29, 32,  
    113, 127, 160, 164  
    endophytic 14  
    pathogenic 127  
Fusogenicity 113

## G

Gaillardia megapotamica 21  
Gametocytes 194  
Gas chromatography 95  
Gastrointestinal tract accounts 63  
Gel 112, 124, 132, 139  
    commercial 139  
    -to liquid crystalline transition 112  
Gene regulation 19  
Genetic variability 159  
Genoprotective 4, 5, 16  
    effects 16  
    properties 4, 16  
Germacranolide-type sesquiterpene lactones  
    20  
Globin digestion 197  
Glycosylamines 178  
Green fluorescent protein (GFP) 196  
Growth 3, 14, 116, 119, 132, 134, 135, 138  
    hindered 14  
    inhibition 132  
    microbial 119  
    reduction 134

## H

*Hansfordia sinuosae* 12, 14  
Healing process 116, 124, 134  
    infected wound 124  
HeLa cells 28  
*Helianthus annuus* 3  
Heme 22, 171, 172, 179, 186, 212  
    alkylate 171, 179

## Subject Index

iron 186  
reduced 22  
Hemiacetalic nature 185  
Hemoglobin 22, 171, 179, 191  
digesting pathways 179  
digestion 171  
endocytosis 22, 191  
Herbal 30, 160  
medicines 160  
phytochemicals 30  
*Humicola fuscoatra* 12, 14  
Hydrodistillation 102  
microwave-assisted 102  
Hydrophilic 111, 120  
entrapping 111  
Hydrophilic 173, 177  
artesanate 173  
esters 177  
Hypersensitivity reaction 31

## I

Immune 22, 64  
response 22  
system cells 64  
Immunomodulation 63, 64  
Immunomodulatory 5, 7, 8, 10, 21, 62  
effects 8  
properties 7, 21, 62  
Immunophilins 30  
Immunosuppressants 30  
Inducible nitric oxide synthase 15  
Induction 22, 31  
hypersensitivity 31  
Infected erythrocytes 171, 187  
Instability 109, 117, 120, 174, 185, 205  
chemical 120  
metabolic 174  
thermal 185  
Insulin secretion 16  
Interaction 3, 8, 56, 62, 63, 72, 112, 116, 120,  
125, 133, 136, 139, 170, 172  
abiotic 3  
allelopathic 3

## Medicinal Chemistry Lessons From Nature, Vol. 2 233

biotic 8  
electrostatic 133, 172  
lipophilic 170  
Intracellular 19, 22, 165  
nucleophiles 19, 165  
redox homeostasis 22  
Iron 158, 171, 172, 179, 186, 203  
catalytic 172  
Isomers 30, 61, 67, 71, 77  
isopetasins 30

## L

Leakage 22, 110, 112, 133, 136  
cytoplasmic 136  
death-proceeding 133  
*Leishmania* 134  
*amazonensis* 134  
*tropica* 134  
Lemongrass 127, 128, 129, 130, 135  
Lewis acid 60, 61  
catalysis 60  
catalyst 61  
Lipid 27, 119  
based nanosystems 119  
metabolism 27  
Lipophilicity 19, 22, 112, 169, 176  
Liposome 111, 112  
based vesicular nanosystems 112  
properties 111  
*Listeria monocytogenes* 128  
Liver 31, 174  
metabolism 174  
toxicity 31  
Low-density lipoprotein (LDL) 16  
LPS-induced expression 29  
Lymphocytes 30

## M

Macrodilution techniques 127  
Macrophages 30, 135  
peritoneal 30  
Malaria 160, 165, 182, 196, 197, 202, 203

- chemotherapy 165, 203
  - multidrug-resistant 182
  - parasites 160, 197, 202
  - related hemolysis 196
  - Mechanisms 14, 16, 29, 30, 57, 65, 160, 161, 171, 172, 184, 191, 193, 205
    - allosteric 172
    - antimuscarinic 29
    - bioantimutagenic 16
    - ion-trapping 193
    - plasmocidal 205
  - Medicinal 94, 160
    - plants 160
    - properties 94
  - Melaleuca alternifolia* 114, 135
  - Membrane 65, 110, 112, 113, 120, 125, 136, 171
    - cytoplasmic 110, 136
    - liposome 120
    - microbial 112
    - mitochondria 171
    - synaptic 65
  - Metabolite 137, 173, 174, 185
    - active plasma 174
    - neurotoxic 173
  - Methicillin-resistant *Staphylococcus aureus* (MRSA) 115, 120, 131, 132, 135
  - Michael-type addition reactions 165
  - Miconazole cream 127
  - Microbial colonization 139
  - Microemulsions 125, 126, 128, 130, 131, 134, 135, 136, 137, 138, 139, 140
    - bicontinuous 134
  - Microorganisms 3, 94, 110, 112, 119, 123, 127, 133, 134, 137, 139, 160
    - drug-resistant 119
    - infectious 110, 134
    - opportunistic 127
    - pathogenic 94
  - Migration 125
    - promoted cell 125
  - Mitochondrial 15, 171
    - mediated pathways 15
    - membrane depolarization 171
  - Monoacylglycerol lipase (MAGL) 65, 66
  - Monocytogenes 124
  - MRSA biofilms 120
  - Mucosal leishmaniasis 130
  - Multilamellar liposomes 114
  - Mycobacterium tuberculosis* 22
- ## N
- Nanocarriers 94, 113, 117, 118
    - lipid-based 94
    - liposomal 113
  - Nanoemulsions 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139
    - clove 134, 135
    - eucalyptus 127
    - lemongrass 127
  - Neomycin 118, 138
  - Neurodegeneration 8, 15, 82
  - Neuroinflammation 63
  - Neurological syndrome 196
  - Neuroprotection 65
  - Neurotoxicity 173, 174, 179, 185
  - Neutrophils 30
  - Nigella sativa* 98, 121, 196
  - Nociceptive effects 30
  - Noncancerous cholangiocytes 16
  - Non-classical cannabinoids derivatives 68
  - Nonmiscible liquids 125
- ## O
- Ocimum basilicum* 108, 128
  - Oils 23, 94, 95, 117, 119, 121, 123, 124, 126, 133, 138, 196
    - coconut 133
    - eucalyptus 124, 138
    - liposomal 119
    - liquid 121
    - olive 124
    - rosemary 95
    - volatile 196
  - Olea europea* 6
  - Oral infections 115

## Subject Index

*Origanum vulgare* 99, 132, 135  
Oropharyngeal infections 115  
Oxygen 58, 95, 109, 176, 177  
  phenolic 58  
Ozonolytic transposition 207

**P**

Papain-family proteases 197  
Parapsilosis 125, 132, 133  
Parasitaemia 187  
Parasitemia 180, 201, 204  
  reducing 180  
Parasitosis 159  
Pathogens, multidrug-resistant 110  
Pathway 2, 31, 64, 66, 167  
  isoprenoid metabolite 167  
  metabolic 31  
  plastid-localized mevalonate-independent 167  
  retrograde synaptic signalling 66  
  signaling 64  
Pendants, aromatic 77  
Peppermint essential oil (PEO) 124  
Periodic fevers 165  
Peroxisome proliferator-activated receptors (PPARs) 15  
*P. falciparum* infection 158  
Phenomena 140, 166, 183  
  cytoadherence 166  
Phosphatidylcholine liposomes 118  
Phosphodiesterases 30  
Phospholipid bilayer 112  
  liposomal 112  
Plasmodium parasites 22, 160, 179  
  multidrug-resistant 179  
Pneumonia 118, 131, 136  
  fungal 131  
  fungi-induced 136  
Polymer 133, 134  
  polycationic 133  
Prenyltransferase 58  
Presynaptic neurons 65  
Process, mass transport 139

## Medicinal Chemistry Lessons From Nature, Vol. 2 235

Produced cytotoxic effects 14  
Production 3, 4, 29, 30, 65, 124  
  collagen 124  
Pro-inflammatory 15, 29  
  mediators 29  
  pathways 15  
Properties 15, 29, 77, 81, 116, 119, 126, 187  
  anti-inflammatory 15, 29  
  chemo-preventive 119  
  inflammatory 15  
  skin-sensitizing 116  
  trioxane alkylating 187  
Proteins 16, 19, 22, 23, 31, 64, 137, 159, 170, 171, 196  
  cytoplasmic 22  
  damage Plasmodium 22  
  green fluorescent 196  
  putative 170  
  sensitive macromolecular Plasmodium 171  
*Pseudomonas aeruginosa* 27, 128, 129, 130

## Q

Quantitative structure-activity relationship (QSAR) 172

## R

Reactive 22, 31, 134, 172  
  metabolites 31  
  oxygen species (ROS) 22, 134, 172  
Release 29, 30, 31, 116, 124, 135, 136, 141, 184  
  histamine 31  
  nuclear material 136  
Resistance 23, 123, 125, 158, 159, 160, 172, 174, 183, 184, 190, 212  
  microbial 123  
  multidrug 23  
  parasite 172, 183  
Respiratory infections 136  
Ribosomal protein machinery 190  
Rosemary essential oil (REO) 123, 124

*Rosmarinus officinalis* 100, 114, 118, 122,  
123, 125, 129, 137  
ROS-mediated photo-oxidative reaction 167

## S

*Salmonella typhi* 128  
*Senecio aegyptius* 25, 26  
Sesquiterpene lactones (SLs) 17, 19, 20, 21,  
22, 23, 31, 164, 165  
SFME extraction 104  
Skin 31, 114, 119, 124, 125, 134, 135  
  disinfection applications 119  
  infections 125  
  wounds 124, 134  
SLN preparation process 124  
Solid lipid nanoparticles (SLNs) 94, 109, 121,  
122, 123  
Soybean lecithin liposomes 113  
Spasmolytic activity 29  
Stability 4, 94, 109, 112, 117, 158, 170, 174,  
175, 176, 178, 182, 209  
  hydrolytic 175, 176  
  metabolic 174  
  thermal-oxidative 112  
  thermodynamic 209  
*Staphylococcus aureus*, Methicillin-resistant  
115  
STAT-signalling pathways 29  
*Streptomyces* 10  
  *citreus* 10  
  *clavuligerus* 10  
Stress 16, 31, 113, 116, 117, 166, 212  
  oxidative 16, 31, 116, 117, 166, 212  
Systemic sclerosis 71  
Systems 16, 27, 30, 31, 58, 62, 63, 65, 118,  
125, 126  
  bicyclic eremophilane 27  
  cannabinoid 63  
  defective DNA repair 16  
  immune 30, 31, 62  
  tricyclic 58  
  vesicular 118  
*Syzygium aromaticum* 128, 130, 131, 132

## T

*Taraxacum officinale* 3  
Tea tree oil (TTO) 95, 114, 115, 118, 130,  
131, 136, 140  
Terpene synthases 10  
THC-induced inhibition 63  
Therapeutic properties 56, 123  
Therapy 23, 131, 134, 158, 160, 183, 184  
  artemisinin-based combination 183  
  artemisinin combination 158, 160, 183  
  photodynamic 131, 134  
Thin-film hydration method 111, 113, 114,  
119  
Thymus 106, 109, 113, 114, 115, 116, 117,  
131, 132  
  *capitatus* (TC) 109, 113, 114, 115, 116, 117  
  *daenensis* 106, 131, 132  
Topical anti-acne preparations 123  
Toxicity, residual neuronal 173  
Traditional Chinese medicine 194  
Tuberculosis 159

## V

Vancomycin 131, 136  
  intermediate *S. aureus* (VISA) 131, 136  
Versatile crop 57  
Vesicles 111, 112, 113, 114, 116, 117, 119,  
120, 191  
  cholesterol multilamellar 114  
  hemoglobin-filled endocytic 191  
  hemoglobin transport 191

## W

World Health Organization (WHO) 158, 159,  
175, 183  
Wound dressing 119



**Z**

*Zingiber* 11, 12, 128

*nimmonii* 11, 12

*officinale* 128



## **Simone Carradori**

---

Prof. Simone Carradori has carried out his scientific work in Medicinal Chemistry collaborating with several foreign departments. Currently, he is an associate professor at the Department of Pharmacy of "G. d'Annunzio" University of Chieti-Pescara (Italy). The scientific activity is mainly focused on the characterization and synthesis of natural/ synthetic derivatives with potential biological activity and is documented from over 225 papers in international peer-reviewed journals, 6 book chapters, 1 European patent and participations in numerous conferences as invited lecturer. Furthermore, he is "Visiting Professor" at "Faculty of Pharmacy of Bezmialem Vakif University" (Istanbul, Turkey) and member of the PhD committee at "G. d'Annunzio" University of Chieti-Pescara.

He is Editor-in-chief of "Anti-Cancer Agents in Medicinal Chemistry" (Bentham Science Publishers), co-editor of "Current Medicinal Chemistry" (Bentham Science Publisher) and "Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry" (Bentham Science Publishers).